Acknowledgement
This study was financially supported by Isfahan University of Medical Sciences, Isfahan, Iran (Grant no: 3400290).
References
- Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal antiinflammatory drug use in the elderly. Aging Dis 2018; 9: 143-50. https://doi.org/10.14336/AD.2017.0306
- Claria J. Cyclooxygenase-2 biology. Curr Pharm Des 2003; 9: 2177-90. https://doi.org/10.2174/1381612033454054
- Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82. https://doi.org/10.1146/annurev.biochem.69.1.145
- Gupta S, Crofford LJ. An update on specific COX-2 inhibitors: the COXIBs. Bull Rheum Dis 2001; 50: 1-4.
- Vishwakarma RK, Negi DS. The development of COX-1 and COX-2 inhibitors: a review. Int J Pharm Sci Res 2020; 11: 3544-55.
- Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55. https://doi.org/10.1001/jama.284.10.1247
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8. https://doi.org/10.1056/NEJM200011233432103
- Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003; 25(2 Suppl): S32-40. https://doi.org/10.1016/S0885-3924(02)00629-2
- Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8. https://doi.org/10.1136/bmj.332.7553.1302
- Arora M, Choudhary S, Singh PK, Sapra B, Silakari O. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: a review. Life Sci 2020; 251: 117631. https://doi.org/10.1016/j.lfs.2020.117631
- Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011; 89: 855-66. https://doi.org/10.1038/clpt.2011.45
- Olry de Labry Lima A, Salamanca-Fernandez E, Alegre Del Rey EJ, Matas Hoces A, Gonzalez Vera MA, Bermudez Tamayo C. Safety considerations during prescription of nonsteroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews. An Sist Sanit Navar 2021; 44: 261-73. https://doi.org/10.23938/ASSN.0965
- White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92: 411-8. https://doi.org/10.1016/S0002-9149(03)00659-3
- Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15. https://doi.org/10.1172/JCI27291
- Marsico F, Paolillo S, Filardi PP. NSAIDs and cardiovascular risk. J Cardiovasc Med (Hagerstown) 2017; 18 Suppl 1: Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation: e40-3. https://doi.org/10.2459/JCM.0000000000000443
- Sondhi SM, Dinodia M, Singh J, Rani R. Heterocyclic compounds as anti-inflammatory agents. Curr Bioact Compd 2007; 3: 91-108. https://doi.org/10.2174/157340707780809554
- Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8. Erratum in: Nature 1997; 385: 555.
- Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011; 10: 655-83.
- Sztanke K, Markowski W, Swieboda R, Polak B. Lipophilicity of novel antitumour and analgesic active 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione derivatives determined by reversed-phase HPLC and computational methods. Eur J Med Chem 2010; 45: 2644-9. https://doi.org/10.1016/j.ejmech.2010.01.068
- Sztanke K, Fidecka S, Kedzierska E, Karczmarzyk Z, Pihlaja K, Matosiuk D. Antinociceptive activity of new imidazolidine carbonyl derivatives. Part 4. Synthesis and pharmacological activity of 8-aryl-3,4-dioxo-2H,8H-6,7-dihydroimidazo[2,1-c] [1,2,4]triazines. Eur J Med Chem 2005; 40: 127-34. https://doi.org/10.1016/j.ejmech.2004.09.020
- Asadi P, Alvani M, Hajhashemi V, Rostami M, Khodarahmi G. Design, synthesis, biological evaluation, and molecular docking study on triazine based derivatives as anti-inflammatory agents. J Mol Struct 2021; 1243: 130760. https://doi.org/10.1016/j.molstruc.2021.130760
- Gawade SP. Acetic acid induced painful endogenous infliction in writhing test on mice. J Pharmacol Pharmacother 2012; 3: 348. https://doi.org/10.4103/0976-500X.103699
- Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17. https://doi.org/10.1016/0304-3959(92)90003-T
- Hajhashemi V, Amin B. Effect of glibenclamide on antinociceptive effects of antidepressants of different classes. Clinics (Sao Paulo) 2011; 66: 321-5. https://doi.org/10.1590/S1807-59322011000200023
- Hajhashemi V, Dehdashti K. Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models. Res Pharm Sci 2014; 9: 315-21.
- Hajhashemi V, Sajjadi SE, Zomorodkia M. Antinociceptive and anti-inflammatory activities of Bunium persicum essential oil, hydroalcoholic and polyphenolic extracts in animal models. Pharm Biol 2011; 49: 146-51. https://doi.org/10.3109/13880209.2010.504966
- Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987; 30: 103-14. https://doi.org/10.1016/0304-3959(87)90088-1
- Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992; 263: 136-46.
- Choi CH, Kim WM, Lee HG, Jeong CW, Kim CM, Lee SH, et al. Roles of opioid receptor subtype in the spinal antinociception of selective cyclooxygenase 2 inhibitor. Korean J Pain 2010; 23: 236-41. https://doi.org/10.3344/kjp.2010.23.4.236
- Gunn A, Bobeck EN, Weber C, Morgan MM. The influence of non-nociceptive factors on hot-plate latency in rats. J Pain 2011; 12: 222-7. https://doi.org/10.1016/j.jpain.2010.06.011
- Malmberg AB, Bannon AW. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci 1999; 6: 8.9.1-15.
- Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001; 53: 597-652